Reports and Briefs on Pharmaceuticals and Healthcare in Asia-Pacific

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
Report
Report

Market and Product Forecasts: Targeted Cancer Therapies 2011-21 – Eurozone price cuts impact targeted cancer therapies market

Market Product Forecasts for currently marketed targeted cancer therapies including; an overview of sales in each of the seven major pharmaceutical markets and sales forecasts for each brand over the forecast period 2011-21.

Published By Datamonitor
20 Jul 2012 $6400
Buy
Report
Report

Market and Product Forecasts: HER2-Negative/Hormone Receptor-Positive Breast Cancer - Patent expiries and novel drugs shape the market in the next decade

This report and accompanying deliverable provides forecasts for HER2-/HR+ breast cancer drugs in the seven major markets from 2011-20. Including in-depth analysis of the market in individual countries and molecule dynamics of the key therapies.

Published By Datamonitor
19 Jul 2012 $6400
Buy
Report
Report

Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers

Overview of asthma disease definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
18 Jul 2012 $2800
Buy
Report
Report

Product Profiles: Melanoma - Novel combination therapies will increase competition for marketed drugs

This report analyses key marketed and pipeline drugs for melanoma. This includes assessment of current and future market strength of approved drugs, key drug development strategies, and commercial and clinical potential of pipeline drugs.

Published By Datamonitor
18 Jul 2012 $2800
Buy
Report
Report

In Vitro Diagnostics M&A and Deal Trends

This report provides an analysis of strategies and trends employed by companies operating in the in vitro diagnostics (IVDs) market in order to drive revenue growth.

Published By Datamonitor
17 Jul 2012 $2800
Buy
Report
Report

Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals

Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.

Published By Datamonitor
16 Jul 2012 $1520
Buy
Report
Report

Market and Product Forecasts: Schizophrenia – The calm after the patent storm

Assessment of the current and future schizophrenia market using a patient-based forecasting methodology. The analysis is designed to understand the future dynamics of the schizophrenia drug market, with a particular focus on pipeline therapies.

Published By Datamonitor
13 Jul 2012 $6400
Buy
Report
Report

Product Profiles: Inflammatory Bowel Disease – Products compete for underserved patient groups

In-depth analysis of key brands and pipeline candidates for inflammatory bowel disease, including a review of new clinical data and a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
29 Jun 2012 $6400
Buy
Report
Report

Epidemiology: Asthma in China – Aging population and rising urbanization increase asthma prevalence

Overview of asthma prevalence in China and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
28 Jun 2012 $4800
Buy
Report
Report

Prescribing Influences: Schizophrenia – Plethora of antipsychotics fail to address negative symptoms

This report analyzes the unmet needs of schizophrenia treatment and the attributes of drugs that influence the prescribing decisions made by physicians across the seven major markets.

Published By Datamonitor
26 Jun 2012 $2800
Buy

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.